Kura Oncology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kura Oncology, Inc. on December 21, 2016, reporting events occurring on December 20, 2016. The filing details the entry into a new material definitive agreement regarding the Company's principal executive offices in San Diego, California.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to the new lease agreement:
- New Lease Rent: Approximately $15,900 per month for the first year.
- Rent Escalation: 3% annual increase over the lease term.
- Lease Term: Commencing on or after June 1, 2017, expiring October 31, 2019.
- Space Size: Approximately 5,216 square feet.
Material Changes
The Company entered into a "New Sublease" with Wellspring Biosciences LLC for new office space. Concurrently, the Company executed a third amendment to its "Original Sublease" with Wellspring to accelerate the expiration of the current lease. The Original Sublease, previously scheduled to expire on October 31, 2019, will now expire seven days after the Commencement Date of the New Sublease.
Related Party Transactions and Risks
The lessor, Wellspring Biosciences LLC, is a wholly owned subsidiary of Araxes Pharma LLC. Araxes is a stockholder of Kura Oncology and is affiliated with several of the Company's directors and executive officers, including Troy E. Wilson, Heidi Henson, Yi Liu, Antonio Gualberto, Pingda Ren, and Annette North. The filing notes that the summary of terms is qualified by reference to the full text of the agreements to be filed in the 2016 Form 10-K.
Investor Verification Checklist
- Verify the exact "Commencement Date" of the new lease, as it depends on the delivery of premises by Wellspring's landlord.
- Review the full text of the New Sublease and Wellspring Amendment in the upcoming Form 10-K for complete terms and conditions.
- Assess the financial impact of the accelerated termination of the Original Sublease versus the new rental obligations.
- Confirm the extent of related party involvement in the lease negotiation and terms given the affiliation with Araxes Pharma LLC.